Nurix.png
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
June 16, 2024 05:30 ET | Nurix Therapeutics, Inc.
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and...
Nurix.png
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
April 09, 2024 07:00 ET | Nurix Therapeutics, Inc.
Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation Nurix anticipates nominating a clinical candidate within...
Nurix.png
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
March 25, 2024 07:00 ET | Nurix Therapeutics, Inc.
Researchers will apply the latest TPD drug discovery technology to target fusion proteins that cause pediatric cancer Cancer Grand Challenges is an initiative funded by Cancer Research UK SAN...